a Department of Biotechnology Engineering , Dayananda Sagar Institutions , Bengaluru 560 078 , Karnataka , India.
b Visvesvaraya Technological University , Belagavi , India.
J Biomol Struct Dyn. 2019 Mar;37(5):1146-1169. doi: 10.1080/07391102.2018.1451387. Epub 2018 Mar 20.
Acinetobacter baumannii, an opportunistic pathogen, has become multi-drug resistant (MDR) to major classes of antibacterial and poses grave threat to public health. The current study focused to screen novel phytotherapeutics against prioritised targets of Acinetobacter baumannii by computational investigation. Fourteen potential drug targets were screened based on their functional role in various biosynthetic pathways and the 3D structures of 9 targets were retrieved from Protein Data Bank and others were computationally predicted. By extensive literature survey, 104 molecules from 48 herbal sources were screened and subjected to virtual screening. Ten clinical isolates of A. baumannii were tested for antibiotic susceptibility towards clinafloxacin, imipenem and polymyxin-E. Computational screening suggested that Ajmalicine ((19α)-16, 17-didehydro-19-methyloxayohimban-16-carboxylic acid methyl ester from Rauwolfia serpentina), Strictamin (Akuammilan-17-oic acid methyl ester from Alstonia scholaris) and Limonin (7, 16-dioxo-7, 16-dideoxylimondiol from Citrus sps) exhibited promising binding towards multiple drug targets of A. baumannii in comparison with the binding between standard drugs and their targets. Limonin displayed promising binding potential (binding energy -9.8 kcal/mol) towards diaminopimelate epimerase (DapF) and UDP-N-acetylglucosamine 1-carboxyvinyltransferase (MurA). Ajmalicine and Strictamin demonstrated good binding potential (-9.5, -8.5 kcal/mol, respectively) towards MurA and shikimate dehydrogenase (-7.8 kcal/mol). Molecular dynamic simulations further validated the docking results. In vitro assay suggested that the tested isolates exhibited resistance to clinafloxacin, imipenem and polymyxin-E and the herbal preparations (crude extract) demonstrated a significant antibacterial potential (p ≤ .05). The study suggests that the aforementioned lead candidates and targets can be used for structure-based drug screening towards MDR A. baumannii.
鲍曼不动杆菌是一种机会性病原体,对主要类别的抗菌药物具有多重耐药性,对公共健康构成严重威胁。本研究通过计算研究,专注于筛选针对鲍曼不动杆菌优先靶标的新型植物疗法。根据其在各种生物合成途径中的功能作用,筛选了 14 个潜在的药物靶标,从蛋白质数据库中检索了 9 个靶标的 3D 结构,其他靶标则通过计算预测。通过广泛的文献调查,从 48 种草药来源中筛选了 104 种分子,并进行了虚拟筛选。对 10 株临床分离的鲍曼不动杆菌进行了克林沙星、亚胺培南和多粘菌素 E 的药敏试验。计算筛选表明,从蛇根木中提取的阿马碱 ((19α)-16,17-二氢-19-甲氧基育亨宾-16-羧酸甲酯)、从裂果金花中提取的Strictamin (Alstonia scholaris 中的 Akuammilan-17-羧酸甲酯) 和从柑橘属植物中提取的柠檬苦素 (7,16-二酮-7,16-二脱氧柠檬苦素二醇) 与标准药物及其靶标之间的结合相比,对鲍曼不动杆菌的多个药物靶标表现出有希望的结合能力。柠檬苦素对二氨基庚二酸差向异构酶 (DapF) 和 UDP-N-乙酰葡萄糖胺 1-羧基乙烯基转移酶 (MurA) 表现出有希望的结合潜力 (结合能-9.8 kcal/mol)。阿马碱和 Strictamin 对 MurA 和莽草酸脱氢酶 (-7.8 kcal/mol) 表现出良好的结合潜力 (-9.5、-8.5 kcal/mol,分别)。分子动力学模拟进一步验证了对接结果。体外试验表明,测试的分离株对克林沙星、亚胺培南和多粘菌素 E 表现出耐药性,而草药制剂 (粗提取物) 表现出显著的抗菌潜力 (p ≤.05)。该研究表明,上述候选先导物和靶标可用于针对 MDR 鲍曼不动杆菌的基于结构的药物筛选。